Quantum Biopharma (QNTM) Receivables - Other (2019 - 2026)

Quantum Biopharma has reported Receivables - Other for 8 years, with the latest figure at $208524.0 in Q1 2026.

• Quarterly Receivables - Other fell 47.05% year-over-year to $208524.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $208524.0 (down 47.05% YoY) and the FY2025 annual result came in at $231053.0, down 38.33% from the prior year.
• Receivables - Other slipped to $208524.0 in Q1 2026 per QNTM's latest filing, from $231053.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $951503.0 in Q2 2022 and troughed at $3703.0 in Q4 2023.
• A 5-year average of $315011.0 and a median of $277808.5 in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other tumbled 99.01% in 2023, then soared 10018.23% in 2024.
• Over 5 years, Receivables - Other stood at $374377.0 in 2022, then sank by 99.01% to $3703.0 in 2023, then jumped by 10018.23% to $374678.0 in 2024, then slumped by 38.33% to $231053.0 in 2025, then retreated by 9.75% to $208524.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $208524.0, $231053.0, and $78300.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.